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Bipolar disorder (BD) and alcohol use disorders (AUDs) are usually comorbid, and
both have been associated with significant neurocognitive impairment. Patients with the
BD-AUD comorbidity (dual diagnosis) may have more severe neurocognitive deficits than
those with a single diagnosis, but there is paucity of research in this area. To explore
this hypothesis more thoroughly, we carried out a systematic literature review through
January 2015. Eight studies have examined the effect of AUDs on the neurocognitive
functioning of BD patients. Most studies found that BD patients with current or past
history of comorbid AUDs show more severe impairments, especially in verbal memory
and executive cognition, than their non-dual counterparts. Greater neurocognitive
dysfunction is another facet of this severe comorbid presentation. Implications for clinical
practice and research are discussed. Specifically, the application of holistic approaches,
such as clinical staging and systems biology, may open new avenues of discoveries
related to the BD-AUD comorbidity.
Keywords: bipolar disorder, comorbidity, addiction, alcohol use disorders, neurocognition, staging, systems
biology
Neurocognitive Dysfunction is a Core Feature of Bipolar Disorder
Bipolar disorder (BD) is associated with signiﬁcant morbidity, premature mortality and func-
tional disability (Salomon et al., 2013; Conus et al., 2014). The major sources of this disability
seem to be episode density, psychotic features, subclinical depression, sustained neurocognitive
deﬁcits, comorbidities, medication side eﬀects, low premorbid functioning and weak social support
(Sanchez-Moreno et al., 2009a).
It is well established that BD is associated with neurocognitive deﬁcits that persist into
euthymia after episode resolution, and thus represent a core symptom of the illness (Balanzá-
Martínez and Dias, 2013). Several meta-analysis have revealed impairments in the broad domains
of attention, processing speed, verbal memory and executive functions, with relative preserva-
tion of verbal abilities and intelligence (Torres et al., 2007; Bora et al., 2009; Bourne et al.,
2013). This pattern of deﬁcits is similar to that in schizophrenia (SZ), although less severe
in magnitude (Daban et al., 2006; Sánchez-Morla et al., 2009). The variability in the degree
and pattern of cognitive functioning among BD patients is also more pronounced than in
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SZ, and it has been estimated that 30–60% of euthymic BD
patients show clinically relevant deﬁcits (Martino et al., 2008).
Moreover, in population-based studies, BD has been associated
with increased risk for later development of dementia, especially
in middle-age adults (Wu et al., 2013). This risk seems to increase
with the number of episodes (Kessing and Andersen, 2004) and is
independent of confounding variables such as comorbidities (Wu
et al., 2013).
There is also growing evidence that neurocognitive impair-
ments are major predictors of BD patients’ long-term functional
outcomes (Tabarés-Seisdedos et al., 2008; Wingo et al., 2009).
Therefore, neurocognitive improvement represents a therapeu-
tic target in BD (Fuentes-Durá et al., 2012). There is pressing
need to develop interventions speciﬁcally addressed to amelio-
rate these deﬁcits by means of pro-cognitive medications (Dias
et al., 2012) and cognitive training and rehabilitative strategies,
such as functional remediation (Torrent et al., 2013).
Persistent neurocognitive deﬁcits (Balanzá-Martínez et al.,
2005) likely result from the combination of genetic and envi-
ronmental risk factors, as well as neurodevelopmental and neu-
roprogressive processes (Goodwin et al., 2008). Neurocognitive
impairment may increase with illness progression (Robinson and
Ferrier, 2006; Bourne et al., 2013) and history of psychotic symp-
toms (Selva et al., 2007; Martínez-Arán et al., 2008; Brissos et al.,
2011), but it is also found in healthy ﬁrst-degree relatives of
patients with BD, although at a lesser degree (Arts et al., 2008;
Balanzá-Martínez et al., 2008). Subsyndromal depressive symp-
toms, comorbidites and side eﬀects of medications may com-
pound and further worsen these deﬁcits yet cannot fully explain
them (Balanzá-Martínez et al., 2010).
The relative contribution of psychiatric comorbidities to BD
patients’ neurocognition has received limited attention. Dual
diagnosis is the concomitant or comorbid presentation of a sub-
stance use disorder (SUD) or an alcohol use disorder (AUD)
and another psychiatric condition. Patients with dual diagnosis
represent a clinical population of special interest because BD is
highly comorbid with addictions (Cerullo and Strakowski, 2007;
Schoepf and Heun, 2014) and prolonged heavy use of alcohol
and other substances is associated with persistent neurocogni-
tive and brain abnormalities (Cunningham and McCambridge,
2012). Clearly, this relevant issue requires further examination.
The Bipolar—Alcohol Comorbidity
Several epidemiological and clinical studies have consistently
found high rates of comorbid AUD (i.e., alcohol abuse or depen-
dence) among BD patients (Merikangas et al., 2007; Mitchell
et al., 2007; Oquendo et al., 2010). Indeed, BD is the DSM Axis I
disorder most strongly associated with AUDs (Regier et al., 1990;
Kessler et al., 1997). In a recent meta-analysis, lifetime preva-
lence of AUDs aﬀected approximately one third of BD patients,
with higher rates in male (44%) than in female (22%) patients
(Di Florio et al., 2014). Overall, patients with addictions are 5–6
times more likely to have a history of BD compared to the gen-
eral population (Kessler et al., 1997). Research has identiﬁed three
subgroups of patients, presenting with AUD ﬁrst, BD ﬁrst, and
both simultaneously. BD preceded by addiction may represent a
milder illness form (Pacchiarotti et al., 2009).
Although the etiology of the BD-AUD comorbidity is poorly
understood, several explanations have been put forward. Both
BD and AUD are complex-trait conditions with overlapping
etiopathophysiological pathways at the genetic, neurochemical,
neurophysiologic and neuroanatomic levels (Farren et al., 2012).
Shared genetic basis could confer risk for both BD and AUD
(Johnson et al., 2009). Interestingly, this common genetic vul-
nerability would not be entirely driven by confounders, such as
liability for anxiety disorders (Carmiol et al., 2014). Moreover,
comorbid alcohol and substance use may also be a coping strat-
egy by which patients try to manage (e.g., by self-treatment) their
mood symptoms (Bizzarri et al., 2009; Do and Mezuk, 2013). BD
and addictions may share common mechanisms, including high
impulsivity, executive dysfunction, susceptibility to behavioral
sensitization to stressors, as well as poor modulation of motiva-
tion and responses to rewarding stimuli (Swann, 2010; Tolliver
and Hartwell, 2012). Indeed, high trait impulsivity may medi-
ate some severe manifestations of this comorbidity (Swann et al.,
2009; Nery et al., 2013).
At the clinical level, dual diagnosis seems to be mutually
detrimental since addiction worsens the clinical presentation,
course, prognosis and treatment of BD, and vice versa (Salloum
and Thase, 2000). Compared to BD patients without addictions,
dually diagnosed patients have earlier age of onset, poor treat-
ment adherence and treatment response, longer and more fre-
quent mood episodes and hospitalizations, more mixed episodes
and rapid cycling, more comorbid anxiety disorders and greater
impulsivity, and higher rates of aggressive behavior and suicide
attempts (Swann, 2010; Tolliver and Hartwell, 2012; Nery et al.,
2013). Comorbid addictions worsen functioning in BD, some-
times to that of SZ patients (Jaworski et al., 2011). Clearly, dual
BD represents a prevalent, severe and diﬃcult to treat subgroup
of BD, but, surprisingly, little is known about its neurobiological
and neurocognitive correlates (Nery et al., 2011).
The Neurocognitive Dysfunction
Associated with Alcohol Use Disorders
Chronic alcoholism exerts harmful eﬀects on brain health and
cognition, including signiﬁcantly decreased cortical thickness
(Momenan et al., 2012). In addition to brain atrophy, enlarge-
ment of the ventricles and sulci, as well as reductions in cerebral
blood ﬂow and glucose metabolism, particularly in prefrontal
areas, have been described (Gupta andWarner, 2008). Moreover,
chronic alcohol misuse has been consistently associated with
widespread neurocognitive deﬁcits, including episodic memory,
attention, processing speed, visuospatial and motor abilities, ver-
bal ﬂuency, and executive functions, such as decision-making,
problem-solving, workingmemory, andmental ﬂexibility (Stavro
et al., 2013; Bernardin et al., 2014). According to a recent meta-
analysis, all these deﬁcits were of moderate magnitude and IQ
was the only domain not signiﬁcantly aﬀected by chronic alco-
holism (Stavro et al., 2013). As many as 50-80% of patients
show neurocognitive impairment, although there exists marked
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inter-individual variability in the nature and the severity of
deﬁcits (Bates et al., 2002; Bernardin et al., 2014). For instance,
treatment-resistant heavy drinkers have more severe executive
dysfunctions (Wollenweber et al., 2014). In the most severe and
chronic cases, the clinical presentationmay be dominated by cog-
nitive features, such as confabulation, amnesia and confusional
states (e.g., Wernicke-Korsakoﬀ syndrome), as well as global
cognitive deterioration (e.g., alcohol-related dementia).
Prospective studies suggest that abstinence from alcohol
results in partial neurocognitive recovery, especially regarding
sustained attention (Schulte et al., 2014). Overall, a widespread
pattern of impairment seems to remain stable during the ﬁrst year
of sobriety and neurocognitive performance tends to normalize
only after 1 year of abstinence (Stavro et al., 2013). However, cer-
tain functions, such as visuospatial abilities, may remain persis-
tenly impaired even after longer periods of abstinence (Bernardin
et al., 2014). Therefore, several memory rehabilitation strategies
have been developed, although the ﬁeld is still in its infancy
(Svanberg and Evans, 2013).
Here we aim to review the literature that has examined the rel-
ative contribution of AUDs to the neurocognitive functioning of
BD patients. Since both BD and AUDs have been associated with
neurocognitive impairment on their own, patients with the BD-
AUD comorbidity (e.g., dual diagnosis) may have more severe
neurocognitive deﬁcits than those with a single diagnosis.
To explore this hypothesis more thoroughly, we car-
ried out a systematic literature review. Electronic databases
(PubMed, Scopus, EMBASE) were searched through January
2015 using combinations of the following search terms: bipo-
lar disorder cross-referenced with cognition, neurocogniti∗ or
neuropsycholog∗ cross-referenced with alcohol use disorder, alco-
hol abuse or alcohol dependence. These searches retrieved 23,
63, and 389 hits, respectively. In addition, the reference lists
of relevant papers were manually checked for further articles
not previously identiﬁed. Studies comparing neuropsychological
performance of BD subjects with/without AUDs were selected.
The Relative Contribution of Comorbid
Alcohol Use Disorders
So far, only eight studies met the selection criteria and have com-
pared the neurocognitive functioning of BD patients with and
without comorbid AUDs (van Gorp et al., 1998; Levy et al., 2008,
2012; Sanchez-Moreno et al., 2009b; van derWerf-Eldering et al.,
2010; Shan et al., 2011; Chang et al., 2012; Marshall et al., 2012).
The major characteristics of these studies are shown in Table 1.
In a pioneer work, van Gorp et al. (1998) examined 12 BD
patients with past history of alcohol dependence, 13 BD patients
without such comorbidity, and 22 healthy controls. Only males
were recruited and all outpatients were euthymic at the time of
neurocognitive assessment. Both BD groups showed verbal mem-
ory deﬁcits, whereas only the dual group had an additional exec-
utive deﬁcit measured by the number of completed categories
in the Wisconsin Card Sorting Test (WCST). Moreover, neu-
rocognitive functioning was negatively correlated with lifetime
duration of manic or depressive episodes, suggesting that patients
with greater illness burden had poorer performances.
Interestingly, it took one decade for the ﬁeld to revisit this
topic. Levy et al. (2008) compared three groups of BD-I inpa-
tients, who were admitted mostly due to manic episodes. A ﬁrst
group with current alcohol dependence (n = 13), a second group
in full remission (e.g., during at least 1 year) from alcohol depen-
dence (n = 9), and a third non-dual group without history of
SUDs (n = 41). Those with current alcohol dependence were sig-
niﬁcantly more impaired than the non-dual group in measures
of visual memory and verbal memory. Moreover, both dual BD
groups performed signiﬁcantly worse than non-dual BD patients
on executive functions measured by the Stroop test and WCST.
These ﬁndings would suggest that the BD-AUD comorbidity is
associated with more severe mnemonic and executive dysfunc-
tion, and that the neurocognitive consequences of past AUDs
may persist despite sustained abstinence from alcohol. However,
the presence of subacute, residual mood symptoms during exam-
ination before hospital discharge may increase the severity of
deﬁcits found in this study.
Another study by the same research group focused on cog-
nition during the course of early remission from a severe mood
episode (Levy et al., 2012). This 3-month, follow-up study com-
pared 21 BD patients with AUDs in the previous year and 34 BD
patients without a history of SUDs. Dually diagnosed patients
performed worse on measures of verbal memory, visual mem-
ory, and executive functioning on both assessments and showed
a poorer neurocognitive recovery relative to those without SUDs.
These ﬁndings underscore the special needs of BD-AUD patients
in terms of intensive treatment and support aimed to achieve
early recovery after relapses. To that end, detailed and serial neu-
ropsychological evaluations during this critical period remain as
a backbone.
Consistently, another study (Sanchez-Moreno et al., 2009b)
found that euthymic BD patients with (n = 30) and without
(n = 35) previous history of AUDs performed poorer than
healthy controls (n = 35) in verbal memory and executive func-
tions, regardless alcohol history. However, patients with previous
alcohol misuse were more impaired in the Stroop interference
task, suggesting greater diﬃculties in the inhibitory control of
inadequate behaviors, which may be related to higher impulsiv-
ity and probably to higher risk of other addictive behaviors. Dual
patients were requested to be abstinent for at least 1 year but
time of abstinence was not recorded. BD-II patients were also
recruited, and this is particularly relevant since type II is also sig-
niﬁcantly associated with neurocognitive impairments and AUDs
(McElroy et al., 2001; Solé et al., 2012).
In this regard, a Taiwanese study focused only on type-II
BD (Shan et al., 2011). The authors compared 19 patients with
comorbid AUD, 28 patients without comorbid AUD, and 22
healthy controls. All participants were alcohol-free at least 24 h
before examination and BD patients were euthymic. Compared
to the other two groups, dual patients performed signiﬁcantly
worse on tasks of visual memory, verbal memory, attention,
psychomotor speed, and executive functioning. In addition,
working memory was impaired in both BD groups, although
more so in dual patients. However, the clinical groups were
not balanced regarding gender, educational level and number
of hospitalizations, so a potential inﬂuence of these relevant
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variables on neurocognitive results cannot be entirely ruled
out.
A subsequent study from the same research group (Chang
et al., 2012) explored whether the neurocognitive eﬀects of
comorbid AUD is similar or diﬀerent depending on the type
of BD. To this end, BD-AUD patients (type I = 16; type II =
18) were compared with non-dual BD patients (type I = 22;
type II = 38). The four clinical groups showed widespread neu-
rocognitive deﬁcits compared to healthy controls (n = 29) even
during euthymia. Dually diagnosed patients performed signiﬁ-
cantly worse than non-dual BD patients. Of note, non-dual BD-I
patients showed widespread deﬁcits, especially in tests of atten-
tion/concentration and working memory and, whereas non-dual
BD-II patients performed similarly to controls. The authors con-
cluded that alcohol misuse seems to exert greater neurocognitive
impact on BD-I. However, only male patients were recruited in
this study and subjects from Asia have speciﬁc features related to
alcohol consumption.
In the study with the largest sample (n = 353) so far, Mar-
shall et al. (2012) evaluated 98 non-dual BD patients, 158 BD
patients with comorbid addictions (130 of whom had AUDs) and
97 healthy subjects. Compared to controls, BD patients had a
widespread dysfunction in areas of motor speed and dexterity,
visual memory, processing speed and verbal ﬂuency. Moreover,
the dual group performed signiﬁcantly worse than the non-dual
group on tasks of visual memory and reasoning.
On the contrary, only one study has concluded that alco-
holism was not associated with neurocognition among 185 BD
patients (van derWerf-Eldering et al., 2010). However, this result
was based on a post-hoc analysis. Moreover, the authors did not
aim to compare dual and non-dual patients and even the rate of
comorbid AUDs was not reported.
Implications for Clinical Practice and
Research
Taken together, most studies have found that BD patients
with current or past history of comorbid AUDs show more
severe and/or widespread neurocognitive deﬁcits than their non-
dual counterparts. Although there is marked variability in the
ﬁndings, this impairment mostly involves the broad domains of
verbal memory and executive cognition. Moreover, the reviewed
literature further conﬁrms that BD itself (e.g., non-dual BD) is
associated with a signiﬁcant neurocognitive dysfunction, regard-
less mood state (Kurtz and Gerraty, 2009; Bourne et al., 2013).
Cognitive dysfunction would be another phenotypic dimension
common to BD and AUD. Collectively, these ﬁndings imply
either that alcohol misuse poses an additional neurocognitive tax
to that intrinsic to BD itself or that the BD-AUD comorbidity is
a more severe form of illness associated with greater cognitive
dysfunction.
The conclusion of this systematic review must be regarded as
tentative given the reduced number and heterogeneity of extant
studies. The former may result from neuropsychological studies
usually excluding patients based on concurrent or recent misuse
of alcohol and other substances. Several methodological aspects
of the original studies must be also limit the generalization of
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present ﬁndings. Firstly, the sample size in most cases is relatively
modest, especially regarding the comorbid BD-AUD groups,
which may reﬂect the diﬃculty in recruiting clinically stable
and motivated patients who consent going through burdensome
evaluations. Secondly, the timing of examination widely diﬀers
between studies and not all of them have assessed patients dur-
ing euthymia. Doing so is currently considered a gold standard
in neurocognitive research of BD (Bourne et al., 2013), but the
distinct features of dual patients likely advices a less stringent
approach. In this regard, proximity to an acute episode, as well as
use of higher doses and combinations of pharmacological agents
during admissions have been associated with worse neurocogni-
tive performances (Balanzá-Martínez et al., 2010). Thirdly, key
clinical variables, such as number of past episodes and, more
importantly, time of abstinence were not recorded in all stud-
ies. Fourthly, the recruitment of homogenous samples according
to gender or race may introduce another bias. Methodological
reﬁnement and standardization of procedures would allow gain-
ing a deeper understanding of this phenomenon. Fifthly, con-
comitant addiction to other substances, such as cannabis, may
also contribute to neurocognitive dysfunctions in BD (Cahill
et al., 2006) and are beyond the scope of the present review. Sim-
ilarly, complex patterns may also result from interactions with
medical comorbidities and deserve further study. Cardiovascu-
lar and metabolic conditions, such as hypertension or type 2
diabetes, which are usually comorbid with both BD and AUD,
are well known risk factors for cognitive deterioration (Durazzo
et al., 2008). Lastly, except a 3-month follow-up study (Levy et al.,
2012), most research so far has been cross-sectional. Therefore,
longitudinal designs will aid to better establish the temporal rela-
tionship between neurocognitive status and the clinical features
of BD and AUD.
At the clinical level, the present ﬁndings have several implica-
tions for diagnosis, treatment and prognosis. Comorbid addic-
tive disorders, including AUDs, are a potentially treatable risk
factor. Early detection and intervention is a pressing need in
BD (Conus et al., 2014), and this clearly turns mandatory for
dual BD, especially among young people (Hermens et al., 2013).
The ultimate goal of treatments is to improve patients’ func-
tional outcomes and quality of life. This seems achievable since
remission from both alcohol dependence and BD has been asso-
ciated with signiﬁcant improvements in quality of life com-
pared to non-remission (Rubio et al., 2013). Moreover, absence
of AUD was associated with better neurocognitive recovery
during the early course of BD (Torres et al., 2014). However,
few pharmacological and behavioral interventions have eﬀec-
tively addressed the clinical management of dual populations,
probably because theymay not be well-suited for this cognitively-
impaired population (Bradizza et al., 2014). Indeed, neurocog-
nitive dysfunction may represent a barrier for dual patients to
beneﬁt from psychosocial treatments, and probably also from
pharmacological agents through indirect eﬀects on diminished
adherence (Martinez-Aran et al., 2009; Vieta et al., 2012; Jóns-
dóttir et al., 2013; Fagan et al., 2015). Preventative and treatment
strategies should target neurocognitive dysfunction as a major
driver of patients’ functional outcomes (Tabarés-Seisdedos et al.,
2008).
These ﬁndings also suggest that future neurocognitive stud-
ies of BD should take into account the potential confounding
eﬀects of comorbid AUDs, including past exposures to psychoac-
tive substances (Savitz et al., 2005). In our opinion, two additional
implications for researchmerit further discussion. Cosci and Fava
(2011) have recently proposed an alternative strategy to examine
dual diagnosis based on clinimetric methods, helped by stag-
ing and evaluation of subclinical symptoms. According to these
authors, clinical staging may provide a more holistic approach
to dual BD patient’s problematic areas, including neurocognitive
dysfunctions. Here we suggest that BD-AUD may similarly ben-
eﬁt from the application of another holistic perspective—systems
biology.
Several staging models have been put forward to explain
the progressive deterioration that takes place in a signiﬁcant
proportion of BD patients (Kapczinski et al., 2014). Comor-
bid conditions, including addictions, are predicted to be associ-
ated with greater illness progression, chronicity and deterioration
(Kapczinski et al., 2009). Kindling, sensitization and allostatic
load may explain the progressive course and negative outcomes
of dual BD (Post and Kalivas, 2013; Pettorruso et al., 2014). Early
life (e.g., childhood) adversity and stressors play a major role in
the onset and relapses of both BD and AUD, and also explain the
high comorbidity between them (Post and Leverich, 2006; Post
and Kalivas, 2013).
However, no study has examined the neurocognitive burden
of comorbid AUDs according to clinical staging (e.g., compar-
ing early- vs. late-stage BD patients). On the other hand, few
staging models for addictions exist (Langenbucher and Chung,
1995; Favrat et al., 2002) and none has been developed speciﬁ-
cally for dual diagnosis (Cosci and Fava, 2011). In all, we propose
the application of staging to better understand the neurocognitive
dysfunction associated with either BD or AUD alone, and their
comorbid presentation.
A systems biology approach, integrating –omics data with
bioinformatical tools, aims to gain deeper insights into the
etiopathophysiology of a certain disease, which in turn may pro-
vide new therapeutic targets that should be translated into clin-
ical practice (Hoertel et al., 2013). The potential relevance of
systems medicine for AUD (Spanagel et al., 2013; Gorini et al.,
2014) and BD (Frangou, 2014; McIntyre et al., 2014) has been
recently proposed. We agree with McIntyre et al. (2014) that
this approach may be particularly relevant for BD with comor-
bid conditions. Speciﬁcally, systems biology provides an excit-
ing opportunity to better understand the BD-AUD comorbidity
at diﬀerent levels. Unraveling the genes and proteins involved
in the vulnerability to BD-AUD is relevant to inform on the
subserving molecular and cellular mechanisms and to iden-
tify novel treatments and molecules for the management of
this comorbidity. This is clearly relevant since many dual BD
patients may receive suboptimal treatments. This approach may
also prove fruitful to reﬁne current nosology of dual diagnosis
based on more biologically informed grounds (Frangou, 2014).
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In sum, the bipolar-addiction comorbidity may beneﬁt from the
application of holistic approaches, such as staging and systems
biology.
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